NR3C2 and inflammatory bowel disease: Even though the therapeutic potential of MRs remains largely unexplored, there have been reports of IBD treatment via MR targeting, with the most successful being that of the S1PR modulator ozanimod, which is currently being used in clinical settings for the treatment of moderate to severe UC [68].